Kamau Receives RMAT Designation for Nula-cel

Company Kamau Therapeutics Event Type FDA RMAT designation Modality Autologous HSC gene correction (homology-directed repair) Asset Nula-cel Target HBB E6V mutation Disease Area Sickle cell disease Summary Kamau disclosed November 12 that FDA granted RMAT designation to nula-cel for sickle cell disease, based on preliminary…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *